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Summary 
In a mouse model of herpes simplex virus (HSV)  1 corneal infection, tissue destruction results 
from a  CD4  +  T  cell-mediated chronic  inflammation, in which  interleukin  2  and  interferon 
(IFN)~/are requisite inflanunatory mediators and polymorphonuclear leukocytes (PMN)  are the 
predominant infiltrating cells.  In vivo neutralization of IFN-y reheved inflammation at least in 
part through a specific block of PMN extravasation into HSV-l-infected corneas. Intercellular 
adhesion molecule (ICAM) 1 and platelet endothelial cell adhesion molecule (PECAM)  1 were 
upregulated on the vascular endothelium of inflamed corneas. Reduced PMN extravasation in 
anti-IFN-',/-treated mice  was  associated  with  a  dramatic  reduction  of PECAM-1  but  not 
ICAM-1 expression on vascular endothelium. PMN accumulated in the lumen of corneal ves- 
sels after in vivo IFN-~/neutralization.  PECAM-1  was readily detectable on PMN inside the 
vessels but was not detectable on PMN that extravasated into the infected cornea. Moreover, 
flow cytometric analysis  revealed reduced PECAM-1  expression but elevated major histocom- 
patibility complex class I expression on PMN that recently extravasated into the peritoneal cav- 
ity when compared with PMN in the peripheral blood. We conclude that IFN-y contributes 
to HSV-l-induced corneal inflammation by facilitating PMN infiltration; this appears to be ac- 
complished through upregulation of PECAM-1  expression on the vascular endothelium;  and 
PMN downregulate PECAM-1  expression during the process of extravasation. 
I 
n  infectious diseases,  inflammation can contribute to the 
elimination or control of the infectious agent. However, 
in some cases, inflammation can become chronic and result 
in  the  destruction  of  healthy  tissue.  In  general,  these 
chronic inflammatory responses are immunologically medi- 
ated.  In our mouse model of HSV-1  corneal disease,  pri- 
mary infection is followed by the appearance within 2 d of 
epithelial lesions that heal by 4 d after infection. The lesions 
are characterized by the presence of replicating virus in the 
corneal epithelium  (1).  Resolution of the epithelial lesions 
is followed by a  clinically quiescent  period of ~1  wk.  At 
that time, ~50% of the infected corneas develop a chronic 
inflammation that results in  progressive destruction  of the 
corneal architecture.  It is this chronic inflammation in the 
corneal  stroma that  is  associated with  visual morbidity in 
human patients suffering from HSV keratitis. 
The  corneal stromal inflammation resulting from infec- 
tion of mice with the RE strain of HSV-1  is characterized 
by an inflammatory infiltrate  comprised predominantly of 
PMN  and  CD4 +  T  lymphocytes.  This  inflammatory re- 
sponse is abrogated by in vivo depletion ofCD4 + T lympho- 
cytes (2). The Thl  cytokines IL-2, IFN-~/, and TNF-od[~, 
but not Th2 cytokines IL-4 and IL-10, are detected in leu- 
kocytes extracted from inflamed corneas  after HSV-1  in- 
fection (3). Moreover, studies from our laboratory demon- 
strated that neutralizing the Thl  cytokines IL-2 or IFN-% 
but not the Th2 cytokine IL-4, can prevent the inflamma- 
tion  from  developing  (4).  Although  Th2  cytokines  have 
not  been  detected  in  HSV-l-infected  corneas,  they  may 
play  a  protective  role  when  given  exogenously.  For  in- 
stance,  a  recent  study  demonstrated  that  combined intra- 
corneal and systemic injection of IL-10 before HSV-1 infec- 
tion  significantly  suppressed  corneal  inflammation  (5). 
These findings suggest that a Thl CD4 § T  lymphocyte re- 
sponse to HSV-1  antigens in the infected cornea regulates 
the infiltration and/or tissue-destructive functions of PMN. 
IFN-'y possesses a number ofproinflammatory character- 
istics.  These  include  upregulation  of  MHC  expression, 
activation of cytokine secretion, phagocytosis, and produc- 
tion of reactive oxygen and nitrogen intermediates by mac- 
rophages  (for reviews  see  references  6-8).  In  our  mouse 
model of HSV-1 corneal infection, the inflammatory infil- 
trate  during  active  disease  consists  largely  of T  cells  and 
PMN. Macrophages infiltrate the cornea late in the inflam- 
matory process, and thus appear to be primarily involved in 
the  resolution  of the  inflammatory  response.  Therefore, 
proinflammatory  functions  of  IFN-~  that  are  mediated 
through  macrophages may not  contribute  substantially  to 
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has  also  been shown to  activate  PMN  and vascular endo- 
thelial cells (9-16).  The effects oflFN-'y on vascular endo- 
thelium include increased expression of adhesion molecules 
that  contribute to  PMN  extravasation.  However,  most  of 
the  proinflammatory functions of IFN-y  were  established 
in  vitro  and  require  confirmation  in  clinically  relevant 
models of inflammation in vivo. 
In our mouse model of HSV-l-induced  corneal inflam- 
mation, T  cells are not required to control HSV-t  replica- 
tion in the  cornea,  and in fact contribute to  corneal tissue 
destruction and visual morbidity. Thus, this model offers an 
opportunity  to  manipulate  T  cell-mediated  inflammation 
without  the  complication  of pathologic  changes  resulting 
from uncontrolled virus replication. In this study, we have 
used  this  model  to  investigate the  proinflammatory func- 
tions of IFN-~/in vivo. 
Materials  and Methods 
Ocular HSV-I  Infection and Evaluation  of Corneal Inflammation. 
The RE strain of HSV-1 was grown in Vero cells, and intact vir- 
ions  were  purified  on  Percoll  (Phannacia  Biotech  Inc.  Piscat- 
away, NJ) as previously described (17).  Female A/J mice (Freder- 
ick Cancer Research and Development Center, Frederick, MD) 
6-8 wk of age were anesthetized by intramuscular injection of 2 
nag of ketarnine hydrochloride  (Phoenix Scientific, Inc., St. Jo- 
seph,  MO)  and 0.04  nag of acepromazine maleate  (Aveco Co., 
Fort  Dodge,  IA)  in  0.1  ml  of HBSS.  Corneas  of anesthetized 
mice were scarified 10 times in a crisscross  fashion with a sterile 
30-gauge needle, and the eyes were infected topically with 3 I,  zl of 
RPMI containing 105 plaque-forming units of HSV-I. Mice were 
treated  with  gentalnicin (Genoptic;  Allergen  America,  Puerto 
Rico)  topically from day 4  to  day  11  after infection to  prevent 
bacterial superinfection. 
Corneal stromal opacity resulting from inflammatory cell infil- 
tration was evaluated by daily slit-lamp examination after infec- 
tion as previously described (1, 2).  The opacity was scored by an 
observer who was unaware of the treatment given using the fol- 
lowing scale:  1+  =  mild haziness; 2+  =  moderate opacity not 
obscuring the view of the iris; 3+  =  severe opacity in which iris 
details are no longer visible; 4+  =  corneal perforation. 
Antibodies  and Cytokines.  A rat anti-mouse IFN-'y mAb (R4- 
6A2;  American Type Culture Collection,  Rockville, MD)  was 
used for in vivo neutralization. In some experiments, a rat anti- 
HLA-DR5  mAb (SFR3-DR.5; American Type Culture Collec- 
tion) was used as an antibody control, and a rat anti-IL-2 m_Ab 
($4B6; American Type Culture Collection) was used as a speci- 
ficity control.  The anti-HLA-DR5 mAb does not bind detect- 
ably to any mouse tissue. All three antibodies were purified from 
hybridoma  culture  supernatant  by  affinity chromatography  on 
protein  G-Sepharose  Fastflow  (Pharmacia Biotech)  and quanti- 
fied with a radial immunodiffusion kit (ICN Biomedicals; Costa 
Mesa,  CA).  For immunohistochemistry, anti-intercellular adhe- 
sion molecule (ICAM) I  1 (YN/17.4),  anti-Mac-1  (M1/70), and 
anti-LFA-1 (M17/4.2)  mAbs, all obtained from American Type 
lAbbreviations used in this paper: H&E, helnatoxylin and eosin; HUVEC, 
human  umbilical  vein  endothelial  cells; ICAM,  intercellular  adhesion 
molecule; PECAM, platelet endothelial cell adhesion molecule. 
Culture Collection, were  purified from  hybridoma culture me- 
dium  and biotinylated using an immunoprobe biotinylation kit 
(Sigma  Chemical  Co.,  St.  Louis,  MO).  The  biotinylated anti- 
mouse platelet endothelial cell adhesion molecule (PECAM) 1 n~b 
(MEC  13.3)  and  anti-CD3  (145-2Cll)  were  purchased  from 
PharMingen  (San  Diego,  CA).  Anti-mouse  granulocyte  mAb 
(RB6-8C5, provided by R. Coffman, DNAX Research Institute, 
Palo Alto, CA) was isolated from hybridoma culture medium and 
conjugated to  FITC using standard procedures.  A  rat mAb spe- 
cific for a nonpolymorphic region of mouse MHC  class I (M1/ 
42.3.9.8) was obtained from American Type Culture Collection, 
purified  from  hybridoma  supernatant  as  described  above,  and 
used in conjunction with a  FITC-conjugated goat  anti-rat IgG 
(H +  L) (Jackson hnmunoResearch Laboratories,  Inc., West Grove, 
PA)  in an indirect staining procedure.  Mouse  rIFN-y was pur- 
chased from Genzyme Corp.  (Cambridge, MA). 
Histologic and Immunohistologic Examination.  Inflamed eyes  were 
excised at different times after mAb treatment, fixed in 10% neutral 
buffered formalin, and 5-~xm paraffin sections were prepared. The 
sections were stained with hematoxylin and eosin (H&E), mounted 
with  Permount, and coverslipped for  microscopic  examination. 
For immunohistochemical staining, eyes were embedded in OCT 
compound (Optimal Cryogenic Temperature;  Miles,  Inc., Elk- 
hart, IN), snap-frozen immediately in an isopentane-dry ice bath, 
and 6-bLm sections were cut at -20~  Sections were fixed with 
acetone  for  10  rain  and blocked  with  PBS-BGEN  (3%  BSA, 
0.25%  gelatin, 5  mM EDTA,  0.025%  NP-40)  for 20  min, and 
then  processed  for  immunofluorescence or  immunoperoxidase 
staining. For inununoperoxidase staining, sections were incubated 
with biotinylated antibodies for  I  h  at 37~  Cells with bound 
antibodies  were  identified  with  a  peroxidase  reagent  (Elite 
Vectastain ABC; Vector Laboratories Inc., Burlingame, CA)  us- 
ing a diaminobenzidine peroxidase substrate kit (Vector Labora- 
tories,  Inc.). For two-color immunofluorescence staining, sections 
were then incubated for I h with a lmxture of 0.5 I.tg/nd of FITC- 
labeled anti-mouse granulocyte mAb (RB6-8C5) and 4 ~g/ml of 
biotinylated  anti-mouse  PECAM-1.  The  sections  were  then 
washed and incubated with 0.6 b~g/ml of PE-conjugated strepta- 
vidin  (PharMingen)  for  30  min.  Slides  were  then  washed, 
mounted with Pemlafluor (Lipshaw, Detroit, MI), and coverslipped. 
Evaluation of Staining Intensity.  The  intensity  of  staining  of 
PECAM-1  on  the  vascular endothelium was  analyzed with  an 
image  processing  system  (Zeiss  SEM-IPS;  Carl  Zeiss,  Inc., 
Thornwood, NY) established in Dr. Paul Knepper's laboratory at 
Children's Memorial Hospital (Chicago,  IL).  The sampling win- 
dow was 0.015  mm  2 and the resolution limit was 0.24 I.~tn. All 
measurements were  made with a planapochromatic 40X/1.0  oil 
immersion objective under a light microscope (Carl Zeiss, Inc.). 
They were made as the percentage of transmission with the use of 
a scanning spectrophotometer  (Carl Zeiss,  Inc.) with the wave- 
length set at 500  +  10 nm. The proper wavelength was  deter- 
mined by  a  system  (Zonax;  Carl  Zeiss,  Inc.).  Briefly,  spectral 
scans  were  performed  using  a  computer-controlled  scanning 
monochromator (Carl Zeiss, Inc.) that scans a spectrum between 
400 and 700  nm in  10-mn increments. The  spectral data  were 
then corrected for microscope lighting (tungsten lamp), and the 
wavelength was selected at a range slightly off the  maximal ad- 
sorption so the dark end of the measurement range would not be 
saturated.  A  zero  transmission value was set with  a black back- 
ground. A  100%  transmission value was measured as the average 
value of an empty field. Four corneas from each treatment group 
were  excised, and frozen sections were  stained together for PE- 
CAM-1 as described above. The staining intensity of the corneal 
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The data were recorded as the average OD per vessel. Using neu- 
tral density filters, the Zonax system was found to provide linear 
readings (R  2 =  0.9989) over a scale of 0.1 to 3.00D units, which 
exceeded the range of OD  readings  for our histologic  samples. 
The image analysis provided an objective evaluation of staining 
intensity, was in good general agreement with scores based on vi- 
sual examination, but was able to discriminate differences in stain- 
ing intensity that would be difficult to discern by microscopic ex- 
amination alone. 
PMN Isolation.  PMN were isolated from the peripheral blood 
by centrifugation on a Percoll gradient using a slight modification 
of a previously described  technique (18). Briefly, blood was col- 
lected from the  axillary plexus into tubes containing EDTA, 
diluted with an equal volume of 2X  HBSS,  and incubated for 
15 man at room temperature. The cells were layered over 80% 1.5X 
hypertonic Percoll (Cell/Flex-l124; Atlanta Biologicals, Inc., Nor- 
cross, GA) and centrifuged at  1200 g for 30 rain at 20~  Cells 
from the Percoll-medium interface were  washed with 1X  HBSS, 
and residual RBC were lysed with Tris-NH4C1.  A thioglycolate- 
induced peritoneal exudate was used as a source  of recently ex- 
travasated PMN. Mice received an intraperitoneal injection of 1 ml 
of thioglycolate.  3 h  later,  the peritoneal exudate was removed, 
washed  once  in RPMI  1640  medium supplemented with  5% 
FCS, and then incubated on a plastic surface for 1 h at 37~  in 
the  same  medium.  The  nonadherent cells were  removed  and 
shown to be >98% PMN based on nuclear morphology. 
Flow Cytometric Analysis of Adhesion Molecule Expression on PMN. 
Levels of PECAM-1 or MHC class I on PMN obtained from the 
peripheral blood or  a  thioglycolate-induced peritoneal exudate 
was  assessed by  flow  cytometry  (Coulter  EPICS  V;  Coulter 
Corp.,  Hialeah,  FL). The  enriched PMN  (0.5-1  ￿  106)  were 
added to the U-bottom wells of a 96-well plate and treated  with 
Fc Block  (0.5  p~g/10  r  cells of anti-CD32/CD16; PharMingen, 
San Diego, CA)  for 10 rain on ice. The cells were then treated 
with biotinylated mAb to PECAM-1  (2 p,g/106 cells) or with a 
similar concentration ofa biotinylated rat mAb of irrelevant spec- 
ificity and incubated on ice for 30 min. The cells were washed 
and exposed  to 100 bd of 5 lag/ml strepavidin-PE (PharMingen) 
for 30 rain. Alternatively, after treatment with Fc Block,  the cells 
were  exposed  to  an unconjugated rat  mAb specific  for mouse 
Figure  I.  IFN-~/  producing cells in HSV-l-infected corneas. Frozen 
sections were prepared from eyes with 2+  corneal inflammation  at day 
12-14 after infection. IFN-~-expressing cells in the cornea (arrows) were 
detected by ABC immunoperoxidase  staining. ￿  132. 
MHC class I, followed by FITC-conjugated goat anti-rat Ig. All 
cells were then washed  and resuspended in PBS  containing 5% 
FCS, 0.1% NAN3, and 130 b~g/ml ofpropidium iodide. 
The flow cytometric analysis of PECAM-1 and MHC class I 
expression  was  restricted  to  live  PMN based  on forward  angle 
and 90  ~ light scatter,  and exclusion of propidium iodide-stained 
cells. A  sample  of the  gated  cells was  collected,  and an H&E- 
stained cytospin preparation was found to be >98% PMN based 
on morphology. 
Results 
Role of lFN- y  in  the Maintenance and Progression of Corneal 
Inflammation.  Previous studies involving in vivo neutral- 
ization of IFN-~/before HSV-1  corneal infection demon- 
strated a requirement for IFN-y in the initiation of the in- 
flammatory  response  (4).  However,  the  involvement of 
IFN-y in the progression of corneal inflammation was not 
assessed.  To clarify this issue, we performed experiments in 
which in vivo neutralization of IFN-y was initiated when 
mice reached the  1+,  2+,  or 3+  level of corneal inflam- 
mation. In our model, 50-60% of infected corneas devel- 
oped  1+  to 2+  inflammation from day 10 to  14 after in- 
fection, and reached 3+  or even corneal perforation (4+) 
by day 17-20 after infection. Numerous IFN-~/-producing 
cells were detected in the corneas at all stages  of inflamma- 
tion, as illustrated in Fig. 1. 
Neutralization was  accomplished by  an  intraperitoneal 
injection of 0.5 nag of IFN-y-neutralizing  mAb, followed 
by a second injection of 0.5 nag of the same mAb 7 d later. 
Preliminary experiments  and  previously published results 
(2, 4) established that corneal disease, as evaluated clinically 
or  histologically, developed in an identical manner when 
control  mice  received  an  intraperitoneal injection of rat 
mAb of irrelevant specificity (anti-HLA-DR) or PBS  (data 
not shown). Therefore, in these experiments, control mice 
received intraperitoneal injections of PBS.  Corneal disease 
was monitored by daily slit-lamp examination until the dis- 
ease  pattern  stabilized.  The  PBS-treated  control  mice 
showed progression of corneal inflammation that is typical 
for our model. When mice were treated with PBS  at the 
2+ stage of corneal inflammation (10-14 d after infection), 
all progressed to more severe disease (Fig. 2 A), and 50% of 
the  infected corneas  of PBS-treated  mice  became  so  se- 
verely  inflamed that  the  cornea  perforated  (4+  disease). 
Similar treatment with anti-IFN-y resulted in a rapid re- 
versal of corneal inflammation. As early as 2  d  after anti- 
IFN-~/treatment, inflammation in some corneas was com- 
pletely resolved (Fig. 2 B). The disease pattern stabilized 12 d 
after  the  initial treatment,  when 55%  of the  corneas  of 
mAb-treated mice improved to normal, 36% remained at a 
nonprogressive 2+  stage,  only 9%  progressed  to  the  3+ 
stage  of inflammation, and none of the  corneas of treated 
mice perforated. 
Initiation of anti-IFN-y mAb treatment when mice were 
at the  1+  stage  of corneal inflammation resulted in com- 
plete resolution of inflammation  in all corneas within 8 d of 
the  initial treatment  (not  shown).  Treatment with  anti- 
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IFN-y is required for the progression of HSV-l-induced 
corneal inflammation. Groups of 20-22  mice at the 2+ stage of corneal 
inflammation received an intraperitoneal injection of 0.5 ml of PBS (/t) 
or 0.5 mg of IFN-'y-neutralizing mAb (B), and corneal inflammation was 
monitored  by slit-lamp examination. A second identical treatment was 
administered 7 d later. Data are recorded as the percentage of nfice exhib- 
iting different degrees of" inflammation. Disease progression was sigmifi- 
candy g'reater (P <0.0001)  in the PBS-treated controls than in the anti- 
IFN-y-treated mice as assessed  by Fisher's exact test. 
IFN-y mAb that  was  initiated at the  3+  stage  of corneal 
inflammation did not result in an apparent improvement in 
the  clinical  condition  of  the  corneas.  It  is  noteworthy, 
however,  that  even  in  the latter group,  none  of the mice 
progressed to corneal perforation, and histologically the in- 
flammation appeared to be  resolving (not  shown).  Failure 
of mAb treatment to improve the clinical condition of 3+ 
corneas was probably due to preexisting, irreversible struc- 
tural damage to the cornea at the time of treatment. These 
results demonstrate that IFN-y is required during all stages 
of the progression of the inflammatory response in HSV-1- 
infected corneas. 
Role of lFN- T in Leukocyte Extravasation.  To  investigate the 
mechanisms by which  IFN-3' regulates the  progression of 
inflammation,  we  compared histologic changes in  corneas 
with  2+  inflammation  after  intraperitoneal  injection  of 
anti-IFN-y mAb with  those  in  control  (anti-HLA-DR5) 
mAb-treated mice.  The  cornea  is  normally avascular, but 
corneal inflammation is accompanied by gradual neovascu- 
larization. During the early stages of inflammation, the leu- 
kocytes  extravasate  from  blood  vessels  in  the  peripheral 
cornea, and then migrate to the central cornea. At the 2+ 
stage of HSV-l-induced corneal inflammation, blood ves- 
sels had begun  to  invade the  corneal stroma,  and  a  dense 
infiltrate consisting of PMN  (Fig. 3  A) and CD3 + T  cells 
(Fig. 3  B)  was  observed in  the perivascular space. Within 
48  h  after  anti-IFN-y treatment,  a  marked  reduction  of 
PMN  infiltration into  the perivascular space was  observed 
(Fig. 3  C),  whereas  the  density of CD3 +  T  cells was  not 
noticeably affected (Fig. 3 D). As a specificity control, mice 
received similar treatment with an IL-2-neutralizing mAb. 
The  anti-IL-2 treatment  did not influence  the  infiltration 
of PMN  (Fig. 3  E)  or  CD3 +  T  cells (Fig. 3  F)  into  the 
perivascular space. Thus,  IFN-~, mediates inflammation in 
HSV-l-infected  corneas,  at  least  in  part  by  regulating 
PMN  extravasation  from  blood  vessels  in  the  peripheral 
cornea. 
Modulation  of Adhesion  Molecule Expression  by  IFN-T. 
ICAM-1  was  not  detectable  by  immunohistochemical 
staining on the vascular endothelium of normal mouse cor- 
neas,  but  its expression was  markedly upregulated  on  the 
vascular endothelium of infected corneas at the 2+  stage of 
inflammation  (Fig.  4  A). Because  ICAM-1  is  essential for 
PMN  extravasation  in  some  models  (19-22),  and  its  ex- 
pression  on  vascular  endothelial  cells  can  be  induced  by 
IFN-y  (10-12,  14), we hypothesized that in vivo neutral- 
ization of IFN-y might  have  blocked PMN  extravasation 
into HSV-l-infected corneas by reducing ICAM-1 expres- 
sion in  the  lumen  of corneal  vessels.  However,  ICAM-1 
expression  on  the  corneal  vascular  endothelium  was  not 
noticeably reduced up  to 48  h  after anti-IFN-y treatment 
(Fig.  4  B),  a  period  when  PMN  infiltration  into  the 
perivascular space was blocked. Anti-IFN-~/treatment also 
failed to alter the expression of Mac-1  and LFA-1, the leu- 
kocyte counterreceptors for ICAM-1  on the small number 
of leukocytes that  did infiltrate the  corneas  of anti-IFN- 
y-treated mice (data not shown). The failure of anti-IFN-y 
treatment  to  alter the  expression of these  adhesion mole- 
cules suggests either that IFN-y is not necessary for regulat- 
ing their expression in our model or that a  slow turnover 
rate  of these  molecules  on  vascular  endothelial  cells  and 
leukocytes  precluded  detection  in  the  time  frame  of our 
experiments. In either case, it would appear that anti-IFN-'y 
treatment  does  not  block  PMN  extravasation  through 
modulation of ICAM-1 expression on corneal vascular en- 
dothelium in our model. 
Recent studies have  established a  role for PECAM-1  in 
PMN extravasation in vitro and in vivo (23-25). PECAM-1 
is expressed constitutively at low levels on peripheral blood 
vessels in  normal  mouse  corneas  (not  shown),  and  its ex- 
pression was strongly upregulated in infected corneas with 
2+  inflammation (Fig. 5, A  and B). Within 24 h  after anti- 
IFN-y treatment  of mice  with  2+  corneal inflammation, 
PECAM-1  expression on corneal vascular endothelium was 
noticeably reduced  (not shown).  By  48  h  after treatment, 
PECAM-I  expression was reduced to a level that is consti- 
1438  IFN-y P,.egulation of Neutrophil Extravasation Figure  3.  Representative  photomicrographs  illustrating  the effect of IFN-y neutralization  on leukocyte  infiltration  into HSV-l-infected corneas. 
H SV-l-infected mice exhibiting  the 2+ level of corneal inflammation  received an intraperitoneal  injection of PBS, an IFN-3t-neutralizing  rat mAb, or 
an IL-2-neutralizing rat mAb, and 48 h later corneas were examined histologically. H&E stained paraffin sections of corneas from PBS-treated  mice (A) 
and anti-IL-2-treated mice (C) showed a heavy PMN infiltration into the perivascular space, which was markedly reduced in anti-IFN-~/-treated mice 
(E). In contrast, immunohistochemical  staining revealed similar numbers  of CD3 + T  cells in corneas from PBS-treated  (B), anti-IL-2-treated (D), and 
anti-lFN-y-treated mice (F).  X 132. 
tutively expressed in normal corneas (Fig. 5,  C  and D). The 
reduction  of PECAM-1  expression  correlated  temporally 
with the inhibition ofPMN  extravasation in the corneas. 
To  quantitatively  assess  the  effect  of IFN-~/  neutraliza- 
tion  on  PECAM-1  expression  on  the  corneal vascular en- 
dothelium,  HSV-l-infected  mice with 2+  corneal inflam- 
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mation received an intraperitoneal  injection of anti-IFN-~/ 
mAb  or  a  control  rat  mAb  (anti-HLA-DR5).  2  d  later, 
corneas  from  the  two  treatment  groups,  or  from  normal 
(noninfected  mice)  were  removed,  and  frozen  sections 
were stained simultaneously  and  under identical conditions 
for PECAM-1.  In masked  studies,  the level of PECAM-1 expression  on  vascular endothelium  was  assessed  by image 
analysis  as  described  in  Materials  and  Methods.  The  data 
obtained  from  scans  of  40  sections  of  vessels  in  infected 
corneas  of anti-IFN-y-treated  mice,  42  vessels in infected 
corneas  of  control  mAb--treated  mice,  and  17  vessels  in 
normal corneas  are recorded in Fig.  6  as  the average stain- 
ing intensity (OD)  of each vessel. By 48 h  after anti-IFN-y 
treatment,  PECAM-1  expression on the vascular endothe- 
lium was significantly reduced  (P <0.001)  when  compared 
with PECAM-1  expression on vessels of PBS-treated con- 
trols.  The  level  of PECAM-1  expression  on  vascular  en- 
Figure  4.  Representative photomicrographs illustrating  the  effect  of 
IFN-y  neutralization on vascular  endothelial expression  of ICAM-1  in 
HSV-l-infected corneas.  HSV-l-infected mice exhibiting the 2+  level 
of corneal  inflammation received an intraperitoneal injection of PBS (A) 
or anti-IFN-"/ (B), and 48  h  later corneas  were examined for ICAM-I 
expression  by imnmnohistochemistry. Treatment did not markedly  influ- 
ence ICAM-1 expression.  ￿ 
Figure 5.  Representative photomicrographs illustrating the effect oflFN-y neutralization on PECAM-1 expression on vascular endothdium of HSV- 
1-infected corneas.  HSV-l-infected mice exhibiting the 2+ level of corneal  inflammation received an intraperitoneal injection of control mAb (anti- 
HLA-I)FZ5) or anti-lFN-y, and PECAM-1  expression was evaluated by immunohistochemistry. PECAM-1 expression  remained high 48 h after control 
mAb treatment (A and B) but was markedly  reduced 48 h after anti-IFN-y treatment (C and D). Depicted are vessels with the highest (A) and average 
(B) PECAM-1  expression in controls,  and the average (C) and lowest (D) PECAM-1 expression in anti-IFN-y-treated mice. The average staining iuten- 
sity of these vessels, as assessed by image analysis, was 0.44 (A), 0.25  (B), 0.12 (C), and 0.02 (D). These fields were chosen to represent the range of stain- 
ing intensities shown in Fig. 6. Note the accumulation ofPMN (arrozvheads) in the lumen of vessels with low PECAM-1  expression.  ￿ 
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Figure  6.  IFN-y neutralization reduces PECAM-1  expression on the 
vascular endothelium of HSV-l-infected  corneas (open symbols) to  ap- 
proximately that of normal corneas (solid symbols). HSV-l-infected mice 
exhibiting the 2+ level of corneal inflammation received an intraperito- 
neal injection of control mAb (anti-HLA-D1K5) or anti-IFN-y, and in- 
fected and normal corneas were excised 48 h later. Frozen sections of cor- 
neas from four mice per group were examined for PECAM-1 expression 
by ABC immunoperoxidase staining. The level of PECAM-1  expression 
was assessed in a masked fashion by image analysis as described in Materi- 
als and Methods, and recorded as the mean staining intensity (OD)  per 
corneal vessel. The mean level of PECAM-1  expression in each group is 
indicated by a solid line. The data were analyzed by a one-way analysis of 
variance followed by Tukey's posttest. PECAM-1  expression was signifi- 
cantly elevated in the control mAb group (P <0.001) but not in the anti- 
IFN-y-treated group (P >0.05)  when  compared with normal corneas. 
PECAM-1  expression was significantly lower (P <0.001)  in anti-IFN- 
y-treated mice than in control mAb-treated mice. 
dothelium  of infected corneas 48 h  after anti-IFN-y treat- 
ment  was  not  significantly  different  (P  >0.05)  from  that 
constitutively expressed on vascular endothelium  of normal 
corneas. The magnitude of the difference in staining inten- 
sity  in  treated  and  control  corneas,  as  assessed  by  image 
analysis,  can be visualized in  Fig.  5.  The staining intensity 
of vessels in Fig.  5, A-D, were 0.48,  0.25,  0.12,  and 0.02, 
respectively.  This  result  is  consistent  with  the  hypothesis 
that  IFN-y  is  required  for  maintaining  a  high  level  of 
PECAM-1  expression on the vascular endothelium of HSV- 
1-infected corneas, and that a high level of PECAM-1  ex- 
pression is required for PMN  extravasation. 
We  noted  that  the  level  of PECAM-1  expression  was 
quite consistent in vessels of a given cornea,  and very con- 
sistent on the same vessel in serial sections.  It was possible, 
therefore,  to  evaluate PMN  extravasation in serial sections 
adjacent to those that exhibited high (0.2-0.40D)  and low 
(0-0.20D)  expression  of PECAM-1  on  corneal  vessels. 
Sections  were  simultaneously  stained  for  PECAM-1  and 
PMN  using a two-color immunofluorescent stain. As illus- 
trated in Fig.  7, vessels that expressed a high concentration 
of PECAM-1  showed  a  heavy  density  of PMN  in  the 
perivascular  space.  In  contrast,  those  vessels  exhibiting 
barely detectable PECAM-1  showed no evidence of PMN 
extravasation. 
The photomicrographs  in Figs.  5  D  and 7  illustrate  two 
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additional  points  that  are  of interest.  First,  we  note  that 
PMN  tend  to accumulate  in the lumen  of vessels that ex- 
hibit low levels of PECAM-1  expression. This is consistent 
with our observation that ICAM-1  expression remains high 
in these vessels. Taken in the  context  of the  current  para- 
digm of the adhesion cascade that controls PMN extravasa- 
tion, this observation would suggest that integrin-mediated 
tethering  of the  PMN  to  the  vascular endothelium  is not 
altered by IFN-',/ neutralization,  but  PECAM-l-mediated 
transendothelial  migration is blocked. 
PMN  in  the  peripheral  blood  have been  shown  to  ex- 
press  low  but  detectable  levels  of PECAM-1  (26).  We 
noted  a  low  level  of PECAM-1  staining  on  PMN  that 
were trapped in the lumen of vessels ofanti-IFN-~/-treated 
mice (Figs. 5 D  and 7 E). Interestingly, PMN  that extrava- 
sated into the cornea did not express detectable PECAM-1 
(Figs. 5 A  and 7 B). This suggested that PECAM-1  expres- 
sion  on  PMN  is  dramatically  reduced  after  extravasation. 
However, to clearly establish this point required flow cyto- 
metric  analysis.  Because  it  is  difficult  to  extract  sufficient 
PMN  from  the  cornea  for  flow  cytometric  analysis,  we 
chose  as  an  alternative  to  compare  PECAM-1  expression 
on PMN  obtained from the peripheral blood of mice with 
PECAM-1  expression  on PMN  obtained  from a  thyogly- 
colate-induced  peritoneal  exudate.  Thus,  PMN  obtained 
from  the  peripheral  blood  or  peritoneal  exudate  were 
stained  with  biotin-conjugated  anti-PECAM-1  or an iso- 
type-matched,  biotin-conjugated  mAb of irrelevant  speci- 
ficity,  followed  by PE-conjugated  avidin.  As illustrated  in 
Fig.  8,  PECAM-1  expression  was  markedly  reduced  on 
PMN  that  had  recently  extravasated  into  the  peritoneal 
cavity (mean fluorescence intensity [channel]  =  39.9, mean 
channel  difference  [compared  with  control  mAb]  =  1.3) 
when  compared  with  PMN  from  the  peripheral  blood 
(mean fluorescence intensity  =  99.6,  mean channel  differ- 
ence  =  54.4).  A  similar analysis of MHC  class I expression 
revealed  elevated  expression  on  the  peritoneal  exudate 
PMN  (mean fluorescence intensity  =  131.5,  mean channel 
difference  =  68.1)  when  compared  with  those  from  the 
peripheral  blood  (mean  fluorescence  intensity  =  110.5, 
mean  channel  difference  =  30.3).  The peritoneal  exudate 
PMN  lacked detectable  PECAM-1  expression whether  or 
not  they were  depleted  of macrophages  (data not shown), 
ruling  out  the  possibility  that  PECAM-1  was  selectively 
lost from peritoneal  exudate  PMN  during the  1-h incuba- 
tion  on plastic to remove macrophages.  Thus,  PECAM-1 
appears  to  be  lost  from  PMN  during  extravasation  in  a 
manner analogous  to L-selectin,  whereas MHC class  I  ex- 
pression is elevated during this process. 
PECAM-1  is a recently described member of the  adhe- 
sion molecule family, and the regulation of its expression is 
not  yet  well  documented.  To  confirm  our  finding  that 
IFN-~/  regulates  PECAM-1  but  not  ICAM-1  expression 
on vascular endothelium  in vivo,  100 U  of mouse rlFN-~/ 
was  injected  into  normal  mouse  corneas,  and  the  corneas 
were monitored for PECAM-1  and ICAM-1  expression by 
immunohistochemistry  and  image  analysis.  As  shown  in 
Fig.  9,  PECAM-1  was  constitutively  expressed  at  a  low Figure 7.  Relationship  between PECAM-1 expression on corneal vessels and PMN extravasation. HSV-l-infected mice exhibiting  the 2+  level of 
corneal inflammation received an intraperitoneal  injection  of anti-IFN-y. After 48 h, two-color immunoituorescence  staining of frozen sections of the 
corneas was used to simultaneously identify PECAM-I expression on vascular endothelium (phycoerytherin,  red) and PMN (FITC, green). Phase contrast 
shows the location of corneal blood vessels (A and D). The accumulation  of PMN in the lumen of vessels of anti-IFN-y-treated corneas tends to obscure 
the vessel walls (arrowheads). Corneas with high PECAM-I expression on the vascular endothelium (/3) exhibited  large numbers  of PMN in the perivas- 
cular space (C).  In contrast,  corneas expressing barely detectable  levels of PECAM-1 on the vascular endothelium (E) showed  very few PMN in the 
perivascular space (F).  Note the accumulation  of PMN in the lumen of vessels with reduced PECAM-1 expression (F).  ￿  132. 
level  on  normal  corneal  vascular  endothelium,  and  that 
level of expression was not significantly altered by intracor- 
neal  injection  of  PBS.  However,  PECAM-1  expression 
was  strongly  upregulated  3  h  after injection  of rlFN-'v.  In 
contrast,  ICAM-1  was  not  detectable  on  normal  vascular 
endothelial cells, and its expression was  not induced  at  any 
time after injection of rlFN-~/(data not shown).  This result 
lends further support  to the notion that PECAM-1  but not 
ICAM-1  expression is regulated by  IFN-y  in the inflamed 
cornea  after  HSV-1  infection.  Although  the  level  of 
PECAM-1  expression induced  by rlFN-~/appears  to be as 
high as that  observed in  the inflamed corneas,  no  infiltrat- 
ing PMN  were seen in the rlFN-'v-injected corneas at the 
time points  examined.  This suggests PECAM-1  expression 
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Figure 8.  PECAM-1 and MHC class I expression profile of  mouse PMN freshly  isolated from circulating white blood cells (WBC) or of  PMN isolated 
from peritoneal exudate cells (PEC). Cells were stained with biotinylated rat mAb to PECAM-1 or with a biotinytated rat mAb of irrelevant specificity 
followed by PE-conjugated streptavidin; or were stained with rat mAb to a nonpolymorphic region of  mouse MHC class I followed by FITC-conjugated 
anti-rat lg. The cells were analyzed on a flow cytometer as described in Materials  and Methods. PMN that extravasated  into the peritoneal cavity resem- 
bled those that extravasated into the cornea in that they expressed lower levels of PECAM-1 but elevated levels of MHC class I when compared with 
PMN in the peripheral blood. 
alone  is  not  sufficient  for  PMN  extravasation,  which  is 
hkely to require orchestrated expression of several adhesion 
molecules. 
Discussion 
Despite  the  availability of effective  antiherpetic  drugs, 
HSV-1  corneal infections continue to be a major contribu- 
tor to visual morbidity. The ability of the virus to establish 
a latent infection in the sensory neurons makes eradication 
of the virus from the infected individual impossible at the 
present time.  For this reason,  we believe our best current 
hope  for  improved  ophthalmic  treatment  lies  in  a  better 
understanding of the pathological processes that contribute 
to  the  corneal destruction associated with  HSV  infection. 
Toward  this  end,  we  have  established a  mouse  model  of 
the  disease.  Using the  mouse  model,  we  and  others  have 
demonstrated that corneal destruction is not a  direct effect 
of the virus, but rather is the consequence of a T  lympho- 
cyte response to HSV antigens (2-4, 27-36).  Paradoxically, 
a  T  lymphocyte response also contributes to prevention of 
virus spread to the periocular skin and to the brain (29, 34). 
It becomes imperative, therefore, to understand the imnm- 
nologic  mechanisms  that  may  uniquely  contribute  to  the 
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proinflammatory environment  within  the  infected cornea 
and that may be subject to local regulation. 
Previous  studies  from  our  laboratory  have  established 
that the Thl  cytokines IL-2 and IFN-~/are requisite medi- 
ators of the inflammatory response to HSV-1  in the mouse 
cornea (4).  In those studies, corneal inflammation was pre- 
vented by treating mice systemically with mAb to  IL-2 or 
IFN-~/. However,  a  more  clinically relevant question may 
be whether these mAb can treat existing inflammation.  In 
addition, preventing disease does not  offer an  opportunity 
to  identify mechanisms  by which  these  molecules partici- 
pate in the  inflammatory process.  In this report,  we  dem- 
onstrate that mAb to  IFN-~/ can be effective in ameliorat- 
ing  established  HSV-l-induced  corneal  inflammation. 
Treatment  with  anti-IFN-~/  mAb  had  a  palliative  effect 
when initiated at all stages of inflammation, suggesting that 
IFN-~ is required both for initiation and for maintenance 
or progression of the inflammatory process. These findings 
suggest that appropriate manipulation of the proinflamma- 
tory functions of IFN-~/might provide an effective means 
of intervening in the inflammatory process. We were thus 
encouraged to pursue studies designed to define the mech- 
anisms by which IFN-~/regulates inflammation in HSV-1- 
infected mouse corneas. r 
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Figure  9.  Induction of PECAM-1 expression on corneal vascular en- 
dothelium after intrastromal injection ofrlFN-T into normal mouse cor- 
neas. Mouse rIFN-~/(100 U in 0.5 p.1 ofPBS [A]) or 0.5 p.1 of PBS alone 
(A) was injected into normal mouse corneas. At the indicated time after 
injection, frozen sections of corneas from four mice per group were ex- 
amined for PECAM-1  expression by ABC immunoperoxidase staining. 
The level of PECAM-1  expression was assessed in a masked fashion by 
image analysis  as described in Materials and Methods and recorded as the 
mean  staining intensity  (OD) per  corneal vessel. The  mean level of 
PECAM-1 expression on vessels  in injected corneas is indicated by a solid 
line; the mean level of PECAM-1 expression on vessels  ofnornlal corneas 
is indicated by the dotted line. Data from all three groups were analyzed 
by a one-way analysis  of variance followed by Tukey's multiple compari- 
son test. The P values are for a comparison of the PECAM-1 expression 
in  PBS  and  rIFN-T-injected corneas. PECAM-1  expression in  PBS- 
treated corneas did not differ significantly  from that in normal corneas at 
any time (P >0.05).  PECAM-1 expression in the rlFN-'y-injected  cor- 
neas was significantly (P <0.001)  higher than that in normal corneas at 
3 h but was not significantly  different (P >0.05) at 1 or 24 h. 
Our  histologic  studies  have  provided  some  important 
clues to how IFN-~/regulates inflammation in the cornea. 
Within 48 h  after treatment with mAb to IFN-% a marked 
reduction in the number of PMN in the perivascular space 
of the peripheral cornea was noted.  The  specificity of this 
effect was emphasized by the fact that similar treatment with 
mAb specific for IL-2, while also reducing inflammation in 
the HSV-l-infected cornea (Tang,  Q., W.  Chen,  and R.L. 
Hendricks,  manuscript submitted  for publication),  did  not 
block  PMN  extravasation  (Fig.  3).  These  observations 
demonstrated a role for IFN-~/in regulating PMN  extrava- 
sation  into  infected  corneas.  In  contrast,  the  continued 
presence of T  lymphocytes in the perivascular space of the 
cornea after treatment with mAb to  IFN-~/suggests either 
that  IFN-'y does  not regulate T  lymphocyte extravasation 
or that the T  lymphocytes that were present in the perivas- 
cular space  of treated  mice  had  extravasated before  treat- 
ment but failed to migrate out of the perivascular region. 
Previous investigations established that IFN-3~ treatment 
differentially increases adhesion of T  cells, but not PMN, 
to  cultured endothelial cells  (37).  In addition, intradermal 
injection  of  IFN-~  induces  infiltration  of  T  cells  and 
monocytes,  but  not  PMN  (38,  39).  Taken  together with 
our current findings, these results suggest that (a)  IFN-y is 
necessary, hut  perhaps  not  sufficient,  for  PMN  extravasa- 
tion; and (b) IFN-~/is sufficient, but may not be necessary, 
for T  cell extravasation. In the latter case, other inflamma- 
tory cytokines that are present in the milieu of the inflamed 
cornea  may supplant  the  role  of IFN-'y in  T  lymphocyte 
extravasation. 
Treatment  with  anti-IFN-~/  could  regulate  PMN  ex- 
travasation  by  altering  the  pattern  of adhesion  molecule 
expression  on  the  vascular  endothelium.  ICAM-1  and 
PECAM-1  are Ig superfamily adhesion molecules that have 
been shown  to participate in the interaction of PMN  with 
the vascular endothelium.  ICAM-1  expression on the vas- 
cular endothehum  is regulated by a  variety of proinflam- 
matory  mediators  including  IFN-~/  (10,  11,  40-43).  The 
importance  of [CAM-1  for PMN  extravasation at inflam- 
matory sites appears to vary when tested in different models 
of acute  inflammation  (19-22,  44-47).  Although  we  ob- 
served increased expression of ICAM-1 on the corneal vas- 
cular  endothelium  after  HSV-1  infection,  its  expression 
was not altered by anti-IFN-~/treatment during the period 
that  inhibition of PMN  extravasation was  noted.  Our  re- 
sults do not imply a lack of ICAM-1 involvement in PMN 
extravasation  in  this  model,  but  only  that  inhibition  of 
PMN  extravasation into  HSV-l-infected corneas  of anti- 
IFN-~ treated mice was  not  effected through  modulation 
of ICAM-1  expression. This result might be expected be- 
cause  several  cytokines,  including TNF-ot  and  IL-1,  that 
are  capable  of inducing  ICAM-1  expression  on  vascular 
endothelium have been shown to be produced in HSV-1- 
infected corneas (3, 48). 
PECAM-I  is constitutively expressed on vascular endo- 
thelium and concentrated in the endothelial junctions (23). 
IFN-~/regulation of PECAM-1  expression on human um- 
bilical vein  endothelial cells  (HUVEC)  has  been  studied 
in  vitro.  One  study  (49)  revealed a  moderate  increase  in 
PECAM-1  expression on HUVEC after exposure to IFN-% 
However,  a  more  recent  study  (50)  demonstrated  that 
IFN-~/  did  not  change  PECAM-1  transcription  or  total 
surface  expression on  HUVEC,  but  did induce  a  redistri- 
bution  of  PECAM-1  away  from  intracellular junctions. 
The  reason  for the  difference in  PECAM-1  regulation in 
the two studies is not clear, but may relate to the condition 
of the HUVEC  at the time of assay. For instance, low con- 
stitutive expression of PECAM-1  on HUVEC  may be up- 
regulated by IFN-',/, whereas  high  constitutive  expression 
may be unaffected. 
To  our  knowledge,  our  study  is  the  first  to  examine 
IFN-'y regulation of PECAM-1  expression on vascular en- 
dothelium in vivo. We observed a rather dramatic upregu- 
lation of PECAM-1  expression when  IFN-~ was injected 
into a normal cornea, and an equally dramatic downregula- 
tion  when  IFN-~ was  neutralized in  an  inflamed  cornea. 
The  kinetics  of  the  two  reactions  was  quite  similar. 
PECAM-1  expression  in  the  cornea  was  significantly in- 
creased 3  h  after injection of IFN-% and then returned to 
baseline levels by 24  h.  Similarly, reduction of PECAM-1 
expression in inflamed corneas became apparent 24  h  after 
treatment with anti-IFN-"/ mAb, with  the  maximal effect 
seen at  48  h.  The  seemingly more  dramatic regulatory el- 
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among  other  things  (0  functional  changes  in  endothelial 
cells during in vitro culture,  (it) functional  differences asso- 
ciated with the tissue of origin (i.e., normally avascular cor- 
nea  versus  the  highly  vascularized  umbilical  cord),  or  (iii) 
species differences. PECAM-1  contributes to the junctional 
integrity of the  vascular endothelium  (51)  and may have a 
role in neovascularization  (52). It is interesting to speculate 
that the  cornea may normally maintain its avascularity and 
discourage inflammatory responses by inhibiting  PECAM-1 
expression on the endothelium of peripheral vessels. IFN-~/ 
may overcome this inhibitory  effect, and  thus  dramatically 
increase  PECAM-1  expression.  The  increased  PECAM-1 
expression may facilitate both neovascularization and PMN 
extravasation into the cornea. 
We demonstrate  a good correlation between  the degree 
of PECAM-1  expression  on  corneal vascular endothelium 
and the  number of PMN  in the perivascular space. More- 
over,  PMN  were  consistently  seen  to  accumulate  in  the 
lumen  of corneal  vessels  after  IFN-y  neutralization.  This 
observation  is  consistent  with  the  notion  that  the  contin- 
ued  high  level  of expression  of ICAM-1  observed  on  the 
vascular  endothelium  of these  mice  permits  the  [32  inte- 
grin-mediated  firm  adhesion  of the  PMN  to  the  walls  of 
the corneal vessels, whereas their transendothelial  migration 
is blocked.  Although  correlative,  our results  strongly sug- 
gest that PECAM-1  is an important regulator of PMN  ex- 
travasation in the chronically inflamed HSV-l-infected  cor- 
nea. This is consistent with the observation that PECAM-1 
plays  an  important  role  in  PMN  extravasation  at  sites  of 
acute inflammation  (23-25). 
Evidence suggests that homophilic interaction ofPECAM-1 
on PMN  and vascular endothelium  is required for transen- 
dothelial  migration  (23).  Our  observation  that  PMN 
within  the blood vessels express readily detectable levels of 
PECAM-1  is consistent with the proposal put forth by other 
investigators (23)  that a homophilic interaction of PECAM-1 
on  the  PMN  and  vascular  endotheliurn  may  permit  the 
PMN  to pass through  the endothelial junction  in a zipper- 
like fashion.  We also observed that PMN  that extravasated 
into the cornea or into the peritoneal cavity lacked detect- 
able PECAM-1.  We cannot currently rule out the possibil- 
ity that the apparent loss of PECAM-1  actually reflects the 
loss of the  particular  epitope  on  PECAM-1  that is recog- 
nized  by  the  anti--PECAM-1  mAb  used  in  these  studies. 
However,  a  more  appealing  interpretation  would  be  that 
movement of the PMN through the endothelial junction is 
facilitated  by shedding  of PECAM-1  from  the  surface  of 
the PMN.  Such a model would be consistent with the ob- 
servation ofBogen  et al.  (26)  that CD31  is predominantly 
distributed  on portions  of transmigrating lymphocytes that 
are in contact with or adjacent to areas of contact with en- 
dothelial  cells.  However,  there  is  also published  evidence 
that  heterophilic  interactions  of PECAM-1  may facilitate 
migration  of PMN  through  the  vascular basement  mem- 
brane (53, 54).  Thus, it is not clear at what stage in the ex- 
travasation  process  PECAM-1  is lost  from  the  surface  of 
the PMN. 
We believe the cornea is an ideal tissue in which to study 
immunologically  mediated  inflammation.  Its  transparent 
nature  permits  in vivo monitoring  of many aspects  of the 
inflammatory process such as edema, leukocyte infiltration, 
and  neovascularization.  Moreover,  its  structural  simplicity 
and  absence  of  confounding  preexisting  immunologic 
components  make it  easier to analyze inflammation  histo- 
logically. In addition,  HSV-1  corneal inflammation offers a 
reproducible  model  of irnrnunologically  mediated  inflam- 
mation that is of considerable clinical relevance. Therefore, 
we  anticipate  that  the  use of this  model will lead both  to 
the  elucidation  of  basic  immunologic  mechanisms  that 
contribute  to  chronic  inflammation  and  ultimately  to im- 
proved treatment of this devastating ophthalmic disease. 
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